Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caltrate + Vitamin D is a combination dietary supplement and pharmaceutical product containing calcium carbonate and cholecalciferol (vitamin D3). It is primarily indicated for the prevention and treatment of calcium and vitamin D deficiencies, which are critical for maintaining bone mineral density and preventing skeletal disorders like osteoporosis and osteomalacia. Calcium carbonate provides elemental calcium, a fundamental structural component of the bone matrix. Vitamin D3 acts as a pro-hormone that is metabolically converted to its active form, calcitriol. Calcitriol then binds to the vitamin D receptor (VDR) in the intestinal mucosa, stimulating the expression of calcium transport proteins (such as calbindin) to facilitate the active absorption of dietary and supplemental calcium into the bloodstream. This dual action ensures that sufficient calcium is available and effectively absorbed to support bone health and neuromuscular function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caltrate + Vitamin D.